Company: MDCXW
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001062993-25-008292
Chunk: 199

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-01
Form: DRS
Chunk 199
---
 shares pursuant to the SEPA, and the timing of any sales, are at our option, and we are under no obligation to sell any securities to the Selling Shareholder under the SEPA. In accordance with our obligations under the SEPA, we have filed with the SEC the registration statement of which this prospectus forms a part to register under the Securities Act the resale by the Selling Shareholder of up to 3,710,000 of our common shares, consisting of 105,840 Commitment Shares that we issued to the Selling Shareholder as payment of a commitment fee for its commitment to purchase common shares at our election under the SEPA, and approximately 3,604,160 common shares that we may elect, in our sole discretion, to issue and sell to the Selling Shareholder, from time to time under the SEPA.

We do not have the right to commence any sales of our common shares to the Selling Shareholder under the SEPA until the date on which all of the conditions to the Selling Shareholder's purchase obligation set forth in the SEPA have been satisfied, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC. From and after such date, we will have the right, but not the obligation, from time to time, at our sole and exclusive discretion, for the 36-month period after the date of the SEPA, to direct the Selling Shareholder to purchase a specified amount of common shares, not to exceed the greater of: (1) an amount equal to the average of the daily volume traded of the common shares on the five consecutive trading days immediately preceding an Advance Notice (as defined below) and (2) such number of common shares equal to $500,000 as of the date of each Advance Notice, as described further below under the heading "-Advances of Common Shares Under the SEPA."

We will control the timing and amount of any sales of common shares to the Selling Shareholder. Actual sales of common shares to the Selling Shareholder under the SEPA will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our common shares, and determinations by us as to the appropriate sources of funding for the Company and its operations.

Under the applicable Nasdaq rules, in no event may we issue to the Selling Shareholder under the SEPA more than 2,362,163